Your browser is no longer supported. Please, upgrade your browser.
Galecto, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own11.42% Shs Outstand25.26M Perf Week-32.88%
Market Cap193.43M Forward P/E- EPS next Y-2.12 Insider Trans0.00% Shs Float22.38M Perf Month11.18%
Income-42.50M PEG- EPS next Q-0.54 Inst Own60.20% Short Float0.62% Perf Quarter-30.71%
Sales- P/S- EPS this Y19.40% Inst Trans5.29% Short Ratio0.16 Perf Half Y-64.15%
Book/sh6.04 P/B0.89 EPS next Y7.40% ROA- Target Price- Perf Year-
Cash/sh3.06 P/C1.75 EPS next 5Y47.60% ROE- 52W Range4.50 - 17.99 Perf YTD-57.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.15% Beta-
Dividend %- Quick Ratio21.10 Sales past 5Y- Gross Margin- 52W Low19.29% ATR1.09
Employees28 Current Ratio21.10 Sales Q/Q- Oper. Margin- RSI (14)49.49 Volatility20.56% 19.81%
OptionableNo Debt/Eq0.00 EPS Q/Q-128.90% Profit Margin- Rel Volume5.00 Prev Close5.77
ShortableYes LT Debt/Eq0.00 EarningsMar 29 BMO Payout- Avg Volume862.30K Price5.37
Recom1.20 SMA202.82% SMA50-1.92% SMA200-47.30% Volume4,314,481 Change-6.93%
Apr-26-21Resumed Credit Suisse Outperform $12
Nov-23-20Initiated SVB Leerink Outperform $27
Nov-23-20Initiated Credit Suisse Outperform $29
Nov-23-20Initiated BofA Securities Buy $21
Jun-10-21 03:31PM  
Jun-02-21 08:00AM  
May-11-21 08:00AM  
May-06-21 08:00AM  
May-04-21 08:30AM  
Apr-29-21 05:49AM  
Apr-19-21 06:38AM  
Apr-15-21 08:00AM  
Mar-29-21 08:30AM  
Mar-23-21 10:26AM  
Mar-15-21 07:30AM  
Feb-09-21 08:00AM  
Jan-29-21 01:33AM  
Jan-08-21 08:00AM  
Jan-04-21 04:01PM  
Dec-11-20 08:06AM  
Nov-30-20 08:00AM  
Nov-23-20 04:01PM  
Oct-29-20 01:28PM  
Oct-28-20 09:10PM  
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.